Hanna Group

State-of-the-art dedicated laboratory suite for breath analysis in clinical studies (Imperial College London, ICL) with non-VOC emitting infrastructure and positive pressure ventilation, encompassing four laboratories dedicated to different stages of workflow and including cell culture and tissue processing facilities for mechanistic studies underpinning VOC production.

We established a reliable platform for high-throughput breath analysis with excellent VOC detection limits, quantification, reproducibility and analytical recovery. We have a validated analytical method for TD-GC-TOF-MS that adheres to European Medicines Agency guidance with VOC quantification limit at 1.25ng/L. We have developed quality assurance and control procedures to provide a high level of confidence in the complete workflow from breath sampling to data generation using a bespoke Laboratory Information Management System for logging all recorded data with full traceability. The Hanna laboratory plans to gain ISO-17025 accreditation in 2024.

We developed an AI platform, MSHub, to process and analyse GC-MS data from breath samples using molecular network analysis to identify VOC biomarkers that separate cancer from control and other cancer types. It enables analysis of an unlimited data volume in a reproducible way since the algorithm was designed to function without user involvement. MSHub operates using out-of-core processing, with no processing limit beyond data storage capacity, allowing rollout to sites where high-performance computing is unavailable.

We showed in an experimental human model that the origin of certain VOCs within exhaled breath is derived principally from the lungs, suggesting that VOCs travel in the systemic circulation. We confirmed the endogenous origin of VOCs from cancer and its associated environment.

• Oesophageal and gastric cancers: We developed a cancer detection model with internal validation (n=210 patients), using SIFT-MS with an area under the receiver operator characteristic (AU-ROC) curve of 0.92. The biomarker panel was externally validated in a multicentre study (n=335, AU-ROC=0.85). We expanded the biomarker panel using TD-GC-MS for analytical validation (n=300, AU-ROC= 0.90).
• Colorectal cancer: COBRA study (n=1432) identified biomarkers for colorectal cancer, achieving AU-ROC=0.91 in symptomatic patients and AU-ROC=0.87 when including asymptomatic population.
• Pancreatic cancer: We identified biomarkers for pancreatic ductal adenocarcinoma (n=132, AU-ROC=0.90).
• Liver cancer: VOCAL study identified biomarkers for hepatocellular carcinoma (n= 154, AU-ROC=0.94)

We demonstrated breath testing at public events and conducted simulation studies and human factors experiments on different breath collection devices to examine usability and contamination levels. Stakeholders’ engagement concluded that best position for breath testing is a triage tool in primary care.

Economic modelling projected that a breath test-assisted referral pathway for suspected oesophagogastric cancer would cost the NHS £138M compared to £293M for the current referral pathway with an annual saving of £155M.

We demonstrated breath testing acceptability in primary care (MAGIC, n=1002) and large-scale multicentre studies (COBRA, n=1432), exceeding recruitment targets. 99% of patients consider breath test is easy/ very easy to do.

Biomarkers are protected and owned by ICL. The Hanna Group are inventors of seven patents filed worldwide.

Regional hypoxia (low oxygen) and acidosis is a feature of all solid tumours, and is a consequence of rapid cellular proliferation and an inadequate blood supply. As a result, tumour cells undergo profound metabolic reprogramming to adapt to hypoxic, acidic and nutrient-deprived conditions. We speculate that these harsh conditions that are unique to the tumour microenvironment may play a role in the production of cancer-associated VOCs. Using a systems biology approach, we are investigating the influence of these factors on VOC production using cell & patient-derived organoid models. Experiments include pathway-directed genetic perturbation, functional assays to evaluate aggressive tumour biology. New clinical studies will also use state-of-the-art spatial-omic techniques and machine learning to bridge the gap between tumour metabolism and exhaled VOCs.

The human microbiome plays a significant role in homeostasis, immunomodulation and pathogenesis.  The dynamic and intricate relationship between bacteria and fungi within the tumour microenvironment is critical in understanding factors influencing cancer development and progression. As a result, valuable predictive information can be gathered on diagnoses, prognostication and treatment strategies. We hypothesise there is a strong symbiotic or antagonist relationship between the cancer microbes which influences clinical outcomes. Our work will use high through-put next generation sequencing platforms to define the microbiome of oesophagogastric cancer, explore their functional capabilities and comprehensive network analyses to establish drivers of disease. Evaluating the underlying mechanistic pathways responsible for cancer metabolite production will further elucidate the origin of cancer-specific volatile organic compounds.

Tissue immune surveillance and infiltration impacts prognosis and therapy response in solid cancers. To better understand the influence of the host immune response on VOC generation and carcinogenesis in gastrointestinal cancers, we utilise high-dimensional techniques including spectral flow cytometry, imaging mass cytometry, and confocal microscopy, which allows us to comprehensively characterize heterogeneous immune cell populations at a single-cell level. This knowledge guides the design of bespoke tri-culture models incorporating patient-derived immune cells, organoids and fibroblasts to more accurately mimic the tumour microenvironment. By integrating immune cells into our VOC models, we can precisely replicate in vivo immune-tumour interactions, thereby enhancing our understanding of how various components of the tumour microenvironment contribute to VOC production. Furthermore, by combining microbial analysis and the use of fluorescence in situ hybridisation, we can investigate the microbial-immune interactions which may be responsible for initiating the spread of cancer and identify profiles associated with treatment response.

Group Leader

• Prof. George Hanna

Staff

• Aaron Parker - Laboratory manager & senior analytical scientist
• Ayushi Pabari - Clinical trial manager (AROMA)
• Emma Austin - Clinical trial manager (VAPOR)
• Jessie McClymont - Junior analytical technician
• Jim Ellis - Stable isotope specialist & senior analytical scientist
• Valerio Converso - Senior analytical scientist

Postdoctoral researchers

• Bibek Das - MRC clinical research training fellow
• Ilaria Belluomo - Research associate
• Sara Jamel - Research associate
• Bhamini Vadhwana - Rosetrees and BASO research associate

PhD students

• Anuja T Mitra - MRC clinical research training fellow
• Boyu Xie - Research postgraduate
• Caoimhe M Walsh - Clinical research fellow
• Guillaume B R C Lafaurie - Clinical research fellow
• Henry D P Robb - Clinical research fellow
• Katja Christodoulou - Guts UK doctorate research Fellow
• Michael Fadel - NIHR doctoral fellow
• Munir N Tarazi - Clinical research fellow
• Pallavi Arya - Clinical research fellow
• Philip Leung - Research postgraduate & outreach STEM fellow
• Sameera Sharma - NIHR doctoral fellow
• Shizhou Li - China scholarship council fellow

Internal

• Professor Amanda Cross (Imperial College London)
• Dr Kirill Veselkov (Imperial College London)
• Professor Zoltan Takats (Imperial College London)
• Professor Julian Griffin (Imperial College London)
• Mr Stefan Antonowicz (Imeperial College London)
• Dr Piers Boshier (Imperial College London)

External

• Professor Linda Sharples (London School of Hygiene & Tropical Medicine)
• Professor Patrik Spanel (J. Heyrovský Institute of Physical Chemistry)
• Professor Lesley Hoyles (University of Nottingham)

• National Institute of Health Research
• Cancer Research UK
• Rosetrees Trust
• Medical Research Council
• Guts UK
• Imperial Health Charity
• Wellcome
• Pancreatic Cancer UK
• Epilepsy Research Institute UK